Head-to-head · WeighScore
AlyveRx vs Omada Health
The verdict
AlyveRx takes it — 70.3/100 to 55.6/100.
AlyveRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. AlyveRx (Alyve, Inc.) is a US online telehealth platform connecting patients with licensed providers for GLP-1 weight loss care, no insurance required, with free discreet delivery.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | AlyveRx | Omada Health |
|---|---|---|
| WeighScore | 70.3/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #107 | #436 |
| Semaglutide | $183/mo (all doses, compounded) | Not disclosed |
| Tirzepatide | $249/mo (all doses, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #107 · C
Strengths
- Offers compounded semaglutide and tirzepatide as both injections and needle-free sublingual drops for people who dislike needles
- Transparent monthly pricing shown upfront, no insurance required, and free discreet delivery
- Also carries brand-name Ozempic, Wegovy, and Mounjaro through its provider network
Where it loses points
- Does not publicly name its dispensing pharmacy or display a LegitScript seal, so third-party accreditation is unverified
- Sublingual GLP-1 absorption relies on the company proprietary PermeAct technology and is not FDA-reviewed for weight loss
- State availability is not published on the site
Graded #436 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.